Analysis of Immune Responses in HIV/HBV Co-Infected Participants Experiencing HBsAg Loss After TDF/TAF-Based Antiviral Therapy in the ALLIANCE Clinical Study

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Analysis of Immune Responses in HIV/HBV Co-Infected Participants Experiencing HBsAg Loss After TDF/TAF-Based Antiviral Therapy in the ALLIANCE Clinical Study

	AASLD 2025 Nov 7-11 Wash DC Pamela O. Keba1, Nikita S. Kolhatkar1,David Pan1, Caleb D. Marceau1, P. Rod Dunbar2, Daniel Verdon2, June Mung1, Scott Balsitis1, Sharline Madera1, Frida Abramov1, and Jason Hindman1 *Co-first authors 1Gilead Sciences, Foster City, CA, USA; 2IUniversity of Auckland, Auckland, New Zealand